Pacira Pharmaceuticals Inc. reported EXPAREL earned $80.4 million in the 2018 second quarter, an increase of 15% from the 2017 second quarter.
“EXPAREL allows physicians to deliver long-acting, opioid-free local or regional analgesia using individualized approaches for both small and large procedures,” Dave Stack, chairman and CEO of Pacira, said.
According to the company’s press release, total operating expenses decreased from $86.7 million in the 2017 second quarter to $77.6 million in the 2018 second quarter.
Generally accepted accounting principles (GAAP) net income was $2.6 million, or $0.06 per basic or diluted share.
The company had $372.9 million in cash or cash equivalents as of June 30.